|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein, we described a rare case of ALK-rearranged SCLC responding to ALK inhibitors.
|
31794921 |
2020 |
|
Small cell carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical results revealed that ALK was expressed in 16 of 142 (11.3%) SCLCs.
|
30790327 |
2019 |
|
Small cell carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Some of the important mutations include epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations in small cell lung cancer, human epidermal growth factor receptor (HER2) mutation in breast cancer, and BRAF mutation in melanoma.
|
30771009 |
2019 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Transformation to small cell lung cancer is one phenomenon of acquired resistance to anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors in ALK rearrangement-positive non-small cell lung cancer (NSCLC).
|
30900377 |
2019 |
|
Small cell carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Newer ALK tyrosine kinase inhibitors (TKIs) overcome some resistance mutations through higher exposure and potency, and generally present greater CNS activity, but are unlikely to overcome resistance mediated through separate oncogenic pathway activations, or epithelial to mesenchymal transition (EMT) and small cell lung cancer (SCLC) transformation.
|
29808239 |
2018 |
|
Small cell carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The resistance mechanisms to anaplastic lymphoma kinase (ALK) inhibitors comprise ALK gene variations, such as ALK point mutations and copy-number gains, the activation of bypass signaling through the activation of other oncogenes and small cell lung cancer (SCLC) transformation.
|
30214557 |
2018 |
|
Small cell carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
For patients stable on most appropriate treatment, the mean HUSs were 0.81 and 0.82 in patients receiving EGFR and ALK tyrosine kinase inhibitors (TKIs) respectively (with similar HUSs across agents), which were higher than patients with WT NSCLC (0.78; P = .04) and SCLC receiving chemotherapy (0.72; P = .06).
|
28111120 |
2017 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
No ALK fusion was detected in 54 cases of SCLC or 33 cases of cancer with lung metastasis from other organs.
|
29173772 |
2017 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein, we report a case of ALK-rearranged lung adenocarcinoma with SCLC-like histology in a metastatic abdominal nodule that was resistant to crizotinib therapy.
|
26752677 |
2016 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors.
|
27987586 |
2016 |
|
Small cell carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our analysis of 30 consecutive patients with SCLC for EML4-ALK revealed that two patients, including the current patient and a patient we previously reported, harbored the EML4-ALK fusion gene.
|
23787064 |
2013 |
|
Small cell carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The specificity of anaplastic lymphoma kinase expression in Merkel cell carcinoma versus small cell lung carcinoma was 91.7% with clone D5F3 and 100% with the clones 5A4 and anaplastic lymphoma kinase 1.
|
23574788 |
2013 |